Sep 27 |
Regeneron/ Sanofi granted FDA label expansion for Dupixent in COPD
|
Sep 27 |
Sanofi/Regeneron’s Dupixent set to dominate COPD biologics market following FDA approval
|
Sep 27 |
Regeneron, Sanofi Get FDA OK for Dupixent to Treat COPD
|
Sep 27 |
Sanofi, Regeneron get additional Chinese approval for Dupixent
|
Sep 27 |
Regeneron And Sanofi Snag Their $6 Billion-Potential COPD Approval For Dupixent
|
Sep 27 |
Dupixent® (dupilumab) Approved in the U.S. as the First-ever Biologic Medicine for Patients with COPD
|
Sep 27 |
Dupixent® (dupilumab) Approved in China as the First-ever Biologic Medicine for Patients with Chronic Obstructive Pulmonary Disease (COPD)
|
Sep 27 |
FDA, after delay, clears Regeneron and Sanofi drug for COPD
|
Sep 26 |
Regeneron to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on October 31, 2024
|
Sep 26 |
Taiwan Semiconductor, American Tower, Trane Technologies And A Health Care Stock On CNBC's 'Final Trades'
|